Puma Biotechnology Announces FDA Clearance Of IND For Alisertib In Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Puma Biotechnology has received FDA clearance for its Investigational New Drug (IND) application for Alisertib in small cell lung cancer treatment.
August 08, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Puma Biotechnology's stock may see positive movement due to FDA clearance of its IND application for Alisertib in small cell lung cancer treatment.
FDA clearance of a new drug application is a significant positive development for a biotech company. It allows the company to proceed with clinical trials, bringing it one step closer to potentially marketing the drug. This news could therefore lead to increased investor confidence in Puma Biotechnology, potentially driving up its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100